Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 977,365,056
  • Shares Outstanding, K 943,357
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 26,302 M
  • EBITDA $ 28,299 M
  • 60-Month Beta 0.39
  • Price/Sales 15.05
  • Price/Cash Flow 41.37
  • Price/Book 37.05

Options Overview Details

View History
  • Implied Volatility 34.74% (-0.91%)
  • Historical Volatility 48.41%
  • IV Percentile 41%
  • IV Rank 22.75%
  • IV High 64.53% on 04/07/25
  • IV Low 25.96% on 02/20/25
  • Expected Move (DTE 1) 18.73 (1.83%)
  • Put/Call Vol Ratio 0.96
  • Today's Volume 28,510
  • Volume Avg (30-Day) 39,364
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 320,196
  • Open Int (30-Day) 313,504
  • Expected Range 1,001.83 to 1,039.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 7.37
  • Number of Estimates 7
  • High Estimate 7.77
  • Low Estimate 6.61
  • Prior Year 3.34
  • Growth Rate Est. (year over year) +120.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
993.58 +2.72%
on 02/03/26
1,114.00 -8.39%
on 02/04/26
-17.84 (-1.72%)
since 01/16/26
3-Month
977.12 +4.45%
on 12/10/25
1,133.95 -10.00%
on 01/08/26
-9.49 (-0.92%)
since 11/18/25
52-Week
623.78 +63.61%
on 08/08/25
1,133.95 -10.00%
on 01/08/26
+163.36 (+19.06%)
since 02/18/25

Most Recent Stories

More News
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss

LLY : 1,020.56 (-1.50%)
Lilly to participate in TD Cowen's 46th Annual Health Care Conference

INDIANAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46 th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice...

LLY : 1,020.56 (-1.50%)
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company

COLORADO SPRINGS, Colo. , Feb. 16, 2026 /PRNewswire/ -- The United States Olympic & Paralympic Committee (USOPC) today announced the Team USA Athlete Recovery Program in partnership with Lilly, reinforcing...

LLY : 1,020.56 (-1.50%)
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Selpercatinib  demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death

LLY : 1,020.56 (-1.50%)
The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call

The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call

LLY : 1,020.56 (-1.50%)
Lilly to acquire Orna Therapeutics to advance cell therapies

Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases

LLY : 1,020.56 (-1.50%)
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

HIMS : 15.84 (-2.64%)
NVO : 49.23 (-0.28%)
JNJ : 244.99 (+0.68%)
LLY : 1,020.56 (-1.50%)
Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential

Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer...

MSTR : 125.20 (-2.70%)
VFC : 20.68 (+2.94%)
QCOM : 143.24 (+0.43%)
ETSY : 44.05 (-0.70%)
LOGI : 88.94 (-1.11%)
NVO : 49.23 (-0.28%)
LLY : 1,020.56 (-1.50%)
PFE : 27.37 (unch)
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

NVDA : 187.98 (+1.63%)
LLY : 1,020.56 (-1.50%)
PFE : 27.37 (unch)
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Ventyx Biosciences...

VTYX : 13.96 (+0.07%)
LLY : 1,020.56 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,061.19
2nd Resistance Point 1,049.37
1st Resistance Point 1,034.96
Last Price 1,020.56
1st Support Level 1,008.73
2nd Support Level 996.91
3rd Support Level 982.50

See More

52-Week High 1,133.95
Last Price 1,020.56
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar